INS and diabetes mellitus: Lipohypertrophy is a common complication in patients with diabetes treated with insulin therapy.1 Several risk factors for developing lipohypertrophy among insulin-injecting patients have been considered, including lack of systemic rotation,2–4 needle reuse,2,4,5 needle length,3,6,7 and number of daily injections.8 The condition is primarily characterized by the enlargement of adipocytes that manifests by nodular swelling and the induration of fat tissue around the injection sites.9